Anxiolytic Models
Selank is characterised for anxiolytic-like endpoints in standard rodent behavioural models.

Two-peptide blend · lyophilized
Get an email when Selank / Semax is back
Leave your email and we will send one note the moment it is back in stock.
One email when it restocks, plus occasional Eon updates. Unsubscribe anytime.
Free Shipping on orders over $200
Scan the QR code on any vial to verify its batch, COA, and origin in seconds. Secure traceability from our lab to your bench.
Researchers also added
Research use only.
The Eon standard
Your results are only as good as your compound.
Every lot of Selank / Semax is tested by an independent ISO/IEC 17025-accredited lab in the USA. 99%+ purity isn't a target here. It's the requirement.
Don't take our word for it: test any vial at an accredited lab of your choice. If HPLC purity comes back under 99%, we refund your order and pay for the test.
This is a blend. Selank and Semax are combined in a single vial in equal parts. Selank is a tuftsin-derived peptide studied for anxiolytic-like endpoints and GABAergic signalling; Semax is an ACTH(4-10) analog studied for BDNF expression and neuroprotection. Both originate from the same research lineage and are frequently studied together, though the combination is not characterised as a single formulation.
Two-peptide blend: Selank + Semax, equal parts
The numbers that define Selank / Semax and how it is being studied. For laboratory research use only.
Selank · Semax
Both are heptapeptides
Neurotrophic factor expression
The pathways Selank / Semax acts on - and what each one does. The animation traces its signal outward from the compound to every target it engages.
Selank is a synthetic analog of the immunomodulatory peptide tuftsin. GABAergic signalling and anxiolytic-like endpoints are the characterised readouts in rodent models, alongside effects on enkephalin degradation.
Semax is an ACTH(4-10) analog without corticotropic activity. Elevated BDNF and NGF expression is measured in rodent hippocampus, and neuroprotective endpoints are characterised in ischaemia models.
Both peptides come from the same Russian research lineage and are frequently studied in parallel. The combination itself has not been characterised.
The main areas Selank / Semax is being studied for - and the study-reported figures behind them.
Selank is characterised for anxiolytic-like endpoints in standard rodent behavioural models.
Semax is studied for BDNF and NGF expression in rodent hippocampus.
Neuroprotective endpoints for Semax are characterised in cerebral ischaemia research.
One vial holds both peptides under matched handling for parallel work.
An interactive 3D model rendered from the compound record - rotate and explore its structure.
Molecular model
| Components | Selank + Semax |
| Selank Sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro (tuftsin analog) |
| Semax Sequence | Met-Glu-His-Phe-Pro-Gly-Pro (ACTH 4-10 analog) |
| Form | Lyophilized powder blend |
| Purity | ≥99% by HPLC |
| Appearance | White to off-white powder |
| Solubility | Water-soluble |
| Storage | -20°C, protected from light |
| Classification | Research use only |
Both are heptapeptides from the same research lineage and are frequently studied in parallel, Selank for anxiolytic-like endpoints and Semax for neurotrophic expression. One vial holds both under matched handling.
No. Each peptide is characterised separately and no interaction data exists for the pair.
Two: 5 mg of each peptide, and 10 mg of each. The ratio is equal parts in both.
Each lot is analysed by reverse-phase HPLC and released at ≥99%, with a Certificate of Analysis.
Store lyophilized at -20°C for long-term stability, protected from light and moisture, and avoid repeated freeze-thaw cycles.
Not for human or veterinary use. For in-vitro laboratory research only. These statements have not been evaluated by the FDA; this product is not intended to diagnose, treat, cure, or prevent any disease. Sold exclusively to qualified researchers and institutions.